Autologous CD1c (BDCA-1) (Universitair Ziekenhuis Brussel)

N/A

Report date: 2026/01/27 20:00:10

Base Information

Drug NameAutologous CD1c (BDCA-1) (Universitair Ziekenhuis Brussel)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy
Mechanisms of ActionDendritic cells modulators
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversitair Ziekenhuis Brussel
China Registration ClassN/A

Develop Information

Active CompaniesUniversitair Ziekenhuis Brussel
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A